TY - JOUR
T1 - A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer
AU - Hata, Taishi
AU - Fukunaga, Mutsumi
AU - Murata, Kohei
AU - Uemura, Yoshio
AU - Fukuzaki, Takayuki
AU - Ota, Hirofumi
AU - Ohue, Masayuki
AU - Ohnishi, Tadashi
AU - Tanaka, Nobuo
AU - Takemasa, Ichiro
AU - Mizushima, Tsunekazu
AU - Ikeda, Masataka
AU - Yamamoto, Hirofumi
AU - Sekimoto, Mitsugu
AU - Nezu, Riichiro
AU - Doki, Yuichiro
AU - Mori, Masaki
PY - 2013/6
Y1 - 2013/6
N2 - Purpose: A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer. Several different treatment protocols for IRIS are commonly used in Japan, besides the one used in the FIRIS study. This study was designed to evaluate the feasibility of a 5-week cycle of IRIS. Methods: Between January 2005 and February 2008, a total of 55 patients with metastatic colorectal cancer were enrolled at nine centers in Japan. All patients received irinotecan intravenously (80 mg/m2) on days 1 and 15 and S-1 orally (40-60 mg twice daily, according to body surface area) on days 1-21 of a 5-week repeated cycle. Results: The overall response rate was 29.1 %. The response rate was 43.8 % in patients who received IRIS as first-line therapy and 23.1 % in those who received IRIS as second-line or subsequent therapy. The median survival time was 678 days (22.6 months). Adverse events of Grade 3 or higher that occurred at an incidence of ≥10 % were neutropenia (12.7 %) and diarrhea (10.9 %). Conclusion: Our efficacy and safety data suggest that a 5-week cycle of IRIS is an effective alternative to used currently regimens.
AB - Purpose: A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer. Several different treatment protocols for IRIS are commonly used in Japan, besides the one used in the FIRIS study. This study was designed to evaluate the feasibility of a 5-week cycle of IRIS. Methods: Between January 2005 and February 2008, a total of 55 patients with metastatic colorectal cancer were enrolled at nine centers in Japan. All patients received irinotecan intravenously (80 mg/m2) on days 1 and 15 and S-1 orally (40-60 mg twice daily, according to body surface area) on days 1-21 of a 5-week repeated cycle. Results: The overall response rate was 29.1 %. The response rate was 43.8 % in patients who received IRIS as first-line therapy and 23.1 % in those who received IRIS as second-line or subsequent therapy. The median survival time was 678 days (22.6 months). Adverse events of Grade 3 or higher that occurred at an incidence of ≥10 % were neutropenia (12.7 %) and diarrhea (10.9 %). Conclusion: Our efficacy and safety data suggest that a 5-week cycle of IRIS is an effective alternative to used currently regimens.
UR - http://www.scopus.com/inward/record.url?scp=84878640047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878640047&partnerID=8YFLogxK
U2 - 10.1007/s00280-013-2143-8
DO - 10.1007/s00280-013-2143-8
M3 - Article
C2 - 23543294
AN - SCOPUS:84878640047
SN - 0344-5704
VL - 71
SP - 1657
EP - 1663
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -
